166 related articles for article (PubMed ID: 27264006)
1. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.
Guglielmelli P; Rotunno G; Pacilli A; Rumi E; Rosti V; Delaini F; Maffioli M; Fanelli T; Pancrazzi A; Pieri L; Fjerza R; Pietra D; Cilloni D; Sant'Antonio E; Salmoiraghi S; Passamonti F; Rambaldi A; Barosi G; Barbui T; Cazzola M; Vannucchi AM
Am J Hematol; 2016 Sep; 91(9):918-22. PubMed ID: 27264006
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.
Gianelli U; Fiori S; Cattaneo D; Bossi A; Cortinovis I; Bonometti A; Ercoli G; Bucelli C; Orofino N; Bulfamante G; Iurlo A
Histopathology; 2017 Dec; 71(6):897-908. PubMed ID: 28710830
[TBL] [Abstract][Full Text] [Related]
3. Mutations and prognosis in primary myelofibrosis.
Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
5. Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
Iurlo A; Elli EM; Palandri F; Cattaneo D; Bossi A; Cortinovis I; Bucelli C; Orofino N; Brioschi F; Auteri G; Bianchi P; Fabris S; Isimbaldi G; Sabattini E; Baldini L; Gianelli U
Hematol Oncol; 2019 Oct; 37(4):424-433. PubMed ID: 31359447
[TBL] [Abstract][Full Text] [Related]
6. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Guglielmelli P; Lasho TL; Rotunno G; Mudireddy M; Mannarelli C; Nicolosi M; Pacilli A; Pardanani A; Rumi E; Rosti V; Hanson CA; Mannelli F; Ketterling RP; Gangat N; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM; Tefferi A
J Clin Oncol; 2018 Feb; 36(4):310-318. PubMed ID: 29226763
[TBL] [Abstract][Full Text] [Related]
7. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.
Guglielmelli P; Pacilli A; Rotunno G; Rumi E; Rosti V; Delaini F; Maffioli M; Fanelli T; Pancrazzi A; Pietra D; Salmoiraghi S; Mannarelli C; Franci A; Paoli C; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM;
Blood; 2017 Jun; 129(24):3227-3236. PubMed ID: 28351937
[TBL] [Abstract][Full Text] [Related]
8. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
9. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations.
Barraco D; Cerquozzi S; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Blood Cancer J; 2017 Mar; 7(3):e538. PubMed ID: 28282034
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis.
Wang J; Xu J; Gale RP; Xu Z; Li B; Qin T; Zhang Y; Fang L; Zhang H; Pan L; Qu S; Zhang P; Xiao Z
Leuk Res; 2014 Oct; 38(10):1207-11. PubMed ID: 25182689
[TBL] [Abstract][Full Text] [Related]
12. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
Barosi G; Rosti V; Bonetti E; Campanelli R; Carolei A; Catarsi P; Isgrò AM; Lupo L; Massa M; Poletto V; Viarengo G; Villani L; Magrini U
PLoS One; 2012; 7(4):e35631. PubMed ID: 22536419
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
Alshemmari SH; Rajan R; Emadi A
Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
[TBL] [Abstract][Full Text] [Related]
14. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis.
Lekovic D; Gotic M; Perunicic-Jovanovic M; Vidovic A; Bogdanovic A; Jankovic G; Cokic V; Milic N
Med Oncol; 2014 Mar; 31(3):869. PubMed ID: 24500865
[TBL] [Abstract][Full Text] [Related]
15. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications.
Tadmor T; Shvidel L; Aviv A; Ruchlemer R; Bairey O; Yuklea M; Herishanu Y; Braester A; Rahimi-Levene N; Vernea F; Ben-Ezra J; Bejar J; Polliack A;
Cancer; 2013 May; 119(10):1853-9. PubMed ID: 23423815
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of Primary Myelofibrosis in the Genomic Era.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
[TBL] [Abstract][Full Text] [Related]
17. Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.
Singh N; Sazawal S; Upadhyay A; Chhikara S; Mahapatra M; Saxena R
Indian J Pathol Microbiol; 2015; 58(2):187-91. PubMed ID: 25885131
[TBL] [Abstract][Full Text] [Related]
18. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
[TBL] [Abstract][Full Text] [Related]
19. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.
Patnaik MM; Caramazza D; Gangat N; Hanson CA; Pardanani A; Tefferi A
Eur J Haematol; 2010 Feb; 84(2):105-8. PubMed ID: 19895568
[TBL] [Abstract][Full Text] [Related]
20. X-linked thrombocytopenia with thalassemia displays bone marrow reticulin fibrosis and enhanced angiogenesis: comparisons with primary myelofibrosis.
Åström M; Hahn-Strömberg V; Zetterberg E; Vedin I; Merup M; Palmblad J
Am J Hematol; 2015 Mar; 90(3):E44-8. PubMed ID: 25421114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]